Drugs / Td vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT03063736 Background | Dec 2017 → Mar 2018 | substance-related disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT06514898 Background | May 2025 → Sep 2027 expected | medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT06254326 Background | Sep 2024 → Dec 2027 expected | oligodendroglioma | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT03334305 Background | Aug 2018 → Mar 2025 | high grade astrocytic tumor | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03396575 Background | Jul 2018 → Mar 2025 | diffuse intrinsic pontine glioma | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02361866 Comparator | May → Sep 2014 | bacterial infectious disease | Green Cross Corporation | Completed | Met primary |
| Phase 3 | NCT01993173 Comparator | Nov 2013 → Feb 2014 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Td Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03063736 ↗ |
| Known as | tetanus-diphtheria toxoid | “tetanus-diphtheria toxoid (Td) vaccine” NCT03396575 ↗ |
| Modality | Vaccine | “Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)” NCT01993173 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01993173 ↗ |